Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 2
2011 5
2012 2
2014 2
2015 1
2017 2
2018 3
2019 1
2020 3
2021 6
2022 7
2023 3
2024 7
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Bardia A, et al. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282896 Clinical Trial.
Preoperative chemoradiotherapy for esophageal or junctional cancer.
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. van Hagen P, et al. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. N Engl J Med. 2012. PMID: 22646630 Free article. Clinical Trial.
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP; RAPIDO collaborative investigators. Bahadoer RR, et al. Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7. Lancet Oncol. 2021. PMID: 33301740 Clinical Trial.
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group. van der Voort A, et al. Among authors: siemerink ej. Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5. Lancet Oncol. 2024. PMID: 38588682 Clinical Trial.
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.
van Ommen-Nijhof A, Steenbruggen TG, Wiersma TG, Balduzzi S, Daletzakis A, Holtkamp MJ, Delfos M, Schot M, Beelen K, Siemerink EJM, Heijns J, Mandjes IA, Wesseling J, Rosenberg EH, Vrancken Peeters MJT, Linn SC, Sonke GS. van Ommen-Nijhof A, et al. Among authors: siemerink ejm. Eur J Cancer. 2024 Dec;213:115083. doi: 10.1016/j.ejca.2024.115083. Epub 2024 Oct 20. Eur J Cancer. 2024. PMID: 39489924 Clinical Trial.
The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review.
van Maaren MC, van Hoeve JC, Korevaar JC, van Hezewijk M, Siemerink EJM, Zeillemaker AM, Klaassen-Dekker A, van Uden DJP, Volders JH, Drossaert CHC, Siesling S; NABOR project group. van Maaren MC, et al. Among authors: siemerink ejm. Support Care Cancer. 2024 May 2;32(5):323. doi: 10.1007/s00520-024-08530-2. Support Care Cancer. 2024. PMID: 38695938 Free PMC article.
Implementation of ultra-hypofractionated radiotherapy for breast cancer in the Netherlands in 2020-2023, using registry data and questionnaires.
Eijkelboom AH, van Beek EJA, Stam MR, Westhoff P, van Maaren MC, Sattler MGA, Bantema-Joppe EJ, Verheij M, van den Bongard DHJG, Siesling S; NABON-COVID-19 Consortium and the COVID and Cancer-NL Consortium. Eijkelboom AH, et al. Radiat Oncol. 2025 Jun 12;20(1):99. doi: 10.1186/s13014-025-02669-w. Radiat Oncol. 2025. PMID: 40506770 Free PMC article.
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.
Eijkelboom AH, de Munck L, Menke-van der Houven van Oordt CW, Broeders MJM, van den Bongard DHJG, Strobbe LJA, Mureau MAM, Lobbes MBI, Westenend PJ, Koppert LB, Jager A, Siemerink EJM, Wesseling J, Verkooijen HM, Vrancken Peeters MTFD, Smidt ML, Tjan-Heijnen VCG, Siesling S; NABON-COVID-19 Consortium; COVID and Cancer Care-NL Consortium. Eijkelboom AH, et al. Among authors: siemerink ejm. Breast Cancer Res Treat. 2023 Jan;197(1):161-175. doi: 10.1007/s10549-022-06732-y. Epub 2022 Nov 5. Breast Cancer Res Treat. 2023. PMID: 36334188 Free PMC article.
40 results